News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
862,939 Results
Type
Article (87531)
Company Profile (807)
Press Release (774579)
Multimedia
Podcasts (177)
Webinars (28)
Section
Business (233095)
Career Advice (4140)
Deals (39811)
Drug Delivery (140)
Drug Development (91281)
Employer Resources (203)
FDA (18297)
Job Trends (17407)
News (397487)
Policy (39929)
Tag
Academia (3005)
Academic (2)
Accelerated approval (18)
Adcomms (35)
Allergies (130)
Alliances (56980)
ALS (147)
Alzheimer's disease (1691)
Antibody-drug conjugate (ADC) (267)
Approvals (18338)
Artificial intelligence (515)
Autoimmune disease (104)
Automation (30)
Bankruptcy (406)
Best Places to Work (12634)
BIOSECURE Act (23)
Biosimilars (167)
Biotechnology (485)
Bladder cancer (139)
Brain cancer (53)
Breast cancer (528)
Cancer (4175)
Cardiovascular disease (361)
Career advice (3562)
Career pathing (38)
CAR-T (259)
CDC (57)
Cell therapy (713)
Cervical cancer (33)
Clinical research (75822)
Collaboration (1450)
Company closure (4)
Compensation (964)
Complete response letters (62)
COVID-19 (2964)
CRISPR (85)
C-suite (627)
Cystic fibrosis (142)
Data (4950)
Decentralized trials (2)
Denatured (64)
Depression (114)
Diabetes (467)
Diagnostics (7111)
Digital health (38)
Diversity (12)
Diversity, equity & inclusion (49)
Drug discovery (247)
Drug pricing (195)
Drug shortages (36)
Duchenne muscular dystrophy (209)
Earnings (99242)
Editorial (55)
Employer branding (25)
Employer resources (172)
Events (133534)
Executive appointments (998)
FDA (20893)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (6)
Frontotemporal dementia (16)
Funding (1305)
Gene editing (181)
Generative AI (52)
Gene therapy (567)
GLP-1 (1040)
Government (5392)
Grass and pollen (8)
Guidances (374)
Healthcare (20939)
HIV (49)
Huntington's disease (41)
IgA nephropathy (67)
Immunology and inflammation (257)
Immuno-oncology (22)
Indications (59)
Infectious disease (3214)
Inflammatory bowel disease (192)
Inflation Reduction Act (16)
Influenza (102)
Intellectual property (201)
Interviews (816)
IPO (17931)
IRA (59)
Job creations (5197)
Job search strategy (2866)
Kidney cancer (17)
Labor market (81)
Layoffs (643)
Leadership (37)
Legal (10151)
Liver cancer (92)
Longevity (13)
Lung cancer (592)
Lymphoma (286)
Machine learning (33)
Management (66)
Manufacturing (674)
MASH (147)
Medical device (14914)
Medtech (14941)
Mergers & acquisitions (22786)
Metabolic disorders (1195)
Multiple sclerosis (141)
NASH (23)
Neurodegenerative disease (238)
Neuropsychiatric disorders (63)
Neuroscience (2766)
NextGen: Class of 2025 (7687)
Non-profit (5098)
Now hiring (60)
Obesity (575)
Opinion (316)
Ovarian cancer (142)
Pain (173)
Pancreatic cancer (179)
Parkinson's disease (245)
Partnered (32)
Patents (432)
Patient recruitment (340)
Peanut (57)
People (66368)
Pharmaceutical (145)
Pharmacy benefit managers (29)
Phase I (23386)
Phase II (32896)
Phase III (24814)
Pipeline (2906)
Policy (302)
Postmarket research (3554)
Preclinical (10569)
Press Release (72)
Prostate cancer (205)
Psychedelics (52)
Radiopharmaceuticals (282)
Rare diseases (714)
Real estate (7423)
Recruiting (79)
Regulatory (28145)
Reports (65)
Research institute (2696)
Resumes & cover letters (651)
Rett syndrome (17)
RNA editing (15)
RSV (76)
Schizophrenia (140)
Series A (215)
Series B (160)
Service/supplier (30)
Sickle cell disease (85)
Special edition (26)
Spinal muscular atrophy (170)
Sponsored (42)
Startups (4319)
State (2)
Stomach cancer (17)
Supply chain (103)
Tariffs (96)
The Weekly (111)
Vaccines (1064)
Venture capital (68)
Weight loss (406)
Women's health (61)
Worklife (21)
Date
Today (330)
Last 7 days (1032)
Last 30 days (3325)
Last 365 days (33727)
2025 (28475)
2024 (38142)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1284)
Alabama (81)
Alaska (7)
Arizona (309)
Arkansas (14)
Asia (51079)
Australia (8981)
California (9915)
Canada (2942)
China (951)
Colorado (416)
Connecticut (438)
Delaware (285)
Europe (117406)
Florida (1457)
Georgia (326)
Hawaii (3)
Idaho (67)
Illinois (830)
India (55)
Indiana (488)
Iowa (20)
Japan (339)
Kansas (127)
Kentucky (39)
Louisiana (22)
Maine (79)
Maryland (1320)
Massachusetts (7427)
Michigan (320)
Minnesota (589)
Mississippi (4)
Missouri (124)
Montana (33)
Nebraska (26)
Nevada (110)
New Hampshire (80)
New Jersey (2742)
New Mexico (32)
New York (2668)
North Carolina (1448)
North Dakota (10)
Northern California (4564)
Ohio (310)
Oklahoma (22)
Oregon (51)
Pennsylvania (2049)
Puerto Rico (20)
Rhode Island (46)
South America (1655)
South Carolina (52)
South Dakota (1)
Southern California (3782)
Tennessee (153)
Texas (1550)
United States (36424)
Utah (299)
Virginia (255)
Washington D.C. (84)
Washington State (843)
West Virginia (4)
Wisconsin (103)
Wyoming (2)
There are 862,939 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Preclinical
Arena BioWorks Folds Less Than Two Years After Launch, Blames ‘Policy Uncertainty’
Arena launched with $500 million in early 2024 to fund basic biological research, from which it planned to spin out dedicated companies to focus on drug development.
November 5, 2025
·
2 min read
·
Tristan Manalac
Rare diseases
Harmony Freezes Cannabidiol Gel After Phase III Miss in Fragile X Syndrome
Harmony Biosciences has paused a mid-stage trial of ZYN002 in 22q11.2 deletion syndrome after the THC-free cannabinoid drug failed to significantly improve social avoidance in a late-stage study in fragile X Syndrome.
November 5, 2025
·
2 min read
·
Tristan Manalac
Earnings
Amid Obesity Bidding War, Amgen Believes It Can Stand Out in Crowded Space
Amgen remains confident in its obesity asset MariTide, for which it has launched a broad Phase III program.
November 5, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Charles River Laboratories Provides Update on Strategic Review
November 5, 2025
·
9 min read
Press Releases
Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
November 5, 2025
·
17 min read
Press Releases
Promega Named a BioSpace 2026 Best Places to Work Winner
November 5, 2025
·
2 min read
Press Releases
Cencora Announces $1 Billion Investment to Strengthen Its U.S. Distribution Network
November 5, 2025
·
4 min read
Press Releases
Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights
November 5, 2025
·
15 min read
Press Releases
Charles River Laboratories Announces Third-Quarter 2025 Results
November 5, 2025
·
19 min read
Press Releases
KalVista Pharmaceuticals to Present at Upcoming November 2025 Investor Conferences
November 5, 2025
·
1 min read
1 of 86,294
Next
